Vaxcyte is developing high-fidelity vaccines using its XpressCF™ cell-free protein synthesis platform to produce broad-spectrum conjugate vaccines that target invasive bacterial diseases, including pneumococcal infections and Group A Strep. The company's lead candidate, VAX-24, is a 24-valent vaccine designed to prevent invasive pneumococcal disease, addressing the limitations of existing vaccines that fail to cover non-vaccine strains.
Funding
$1.5B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Despite widespread use of existing pneumococcal conjugate vaccines (PCVs), a significant number of invasive pneumococcal disease cases are caused by non-vaccine strains of the _Streptococcus pneumoniae_ bacteria. Current vaccines do not offer broad enough protection, leading to continued morbidity and mortality, especially in vulnerable populations.
Solution
Vaxcyte is developing a pipeline of broad-spectrum conjugate vaccines targeting invasive bacterial diseases, including pneumococcal infections and Group A Strep, utilizing its XpressCF™ cell-free protein synthesis platform. Their lead candidate, VAX-24, is a 24-valent PCV designed to address the limitations of current vaccines by providing broader coverage against prevalent pneumococcal strains. Vaxcyte is also developing VAX-31, a 31-valent PCV candidate, and has additional vaccine candidates in preclinical development targeting Group A Strep, periodontitis, and Shigella. The XpressCF platform enables the production of vaccines uniquely capable of overcoming bacteria's complex defense mechanisms while preserving immunogenicity.
Target Audience
The primary target audience includes infants and adults at risk of invasive bacterial diseases, particularly pneumococcal infections, as well as healthcare providers and public health organizations seeking to improve vaccine coverage and reduce disease burden.
Features
- XpressCF™ cell-free protein synthesis platform for producing complex conjugate vaccines
- VAX-24: A 24-valent pneumococcal conjugate vaccine (PCV) candidate with broad-spectrum coverage
- VAX-31: A 31-valent PCV candidate designed to cover a significant portion of invasive pneumococcal disease
- Vaccine candidates in preclinical development targeting Group A Strep, periodontitis, and Shigella
- Designed to overcome the limitations of conventional, cell-based vaccine approaches
- Aims to improve upon existing pneumococcal vaccines by covering a significant portion of the invasive pneumococcal disease currently in circulation